UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
UMIT-1: A Randomised Phase Ib Study to Determine the Phase II dose and to Evaluate the Safety
and Efficacy of intravenous (IV) Favipiravir & Ribavirin for the Treatment of CCHF